Age, Biography and Wiki
Ben Goldacre (Ben Michael Goldacre) was born on 20 May, 1974 in United Kingdom, is a British physician, academic and science writer (born 1974). Discover Ben Goldacre's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 46 years old?
|Popular As||Ben Michael Goldacre|
|Occupation||Author, journalist, physician, science writer and scientist|
|Age||47 years old|
|Born||20 May 1974|
We recommend you to check the complete list of Famous People born on 20 May. He is a member of famous Author with the age 47 years old group.
Ben Goldacre Height, Weight & Measurements
At 47 years old, Ben Goldacre height not available right now. We will update Ben Goldacre's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
|Body Measurements||Not Available|
|Eye Color||Not Available|
|Hair Color||Not Available|
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
Ben Goldacre Net Worth
His net worth has been growing significantly in 2020-2021. So, how much is Ben Goldacre worth at the age of 47 years old? Ben Goldacre’s income source is mostly from being a successful Author. He is from British. We have estimated Ben Goldacre's net worth, money, salary, income, and assets.
|Net Worth in 2021||$1 Million - $5 Million|
|Salary in 2020||Under Review|
|Net Worth in 2019||Pending|
|Salary in 2019||Under Review|
|Source of Income||Author|
Ben Goldacre Social Network
|Ben Goldacre Twitter|
|Wikipedia||Ben Goldacre Wikipedia|
In 2020, Goldacre was, with Liam Smeeth, the principal investigator of the OpenSAFELY collaboration which created a software platform to analyse the records of 24 million NHS patients to provide detailed risk factors for hospital deaths from COVID-19.
As of 2016, according to Scopus and Google Scholar his most cited articles have been published in NeuroReport, the European Journal of Preventive Cardiology, the British Medical Journal, The Lancet, and PLOS ONE.
Several of Goldacre's articles were assembled into the October 2014 release I Think You'll Find It's a Bit More Complicated Than That.
Drugs are tested by the people who manufacture them, in poorly designed trials, on hopelessly small numbers of weird, unrepresentative patients, and analysed using techniques which are flawed by design, in such a way that they exaggerate the benefits of treatments. Unsurprisingly, these trials tend to produce results that favour the manufacturer. When trials throw up results that companies don't like, they are perfectly entitled to hide them from doctors and patients, so we only ever see a distorted picture of any drug's true effects. Regulators see most of the trial data, but only from early on in a drug's life, and even then they don't give this data to doctors or patients, or even to other parts of government. This distorted evidence is then communicated and applied in a distorted fashion. In their forty years of practice after leaving medical school, doctors hear about what works through ad hoc oral traditions, from sales reps, colleagues or journals. But those colleagues can be in the pay of drug companies – often undisclosed – and the journals are too. And so are the patient groups. And finally, academic papers, which everyone thinks of as objective, are often covertly planned and written by people who work directly for the companies, without disclosure.
In 2012, Goldacre was appointed a Wellcome Trust Research Fellow in Epidemiology at the London School of Hygiene & Tropical Medicine.
His second book, Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients, was published in the UK in September 2012 and in the United States and Canada in February 2013. In the book he argues that:
In June 2012, he collaborated with the Behavioural Insights Team of the UK government on a policy paper on the use of randomised controlled trials, and in May 2013, he wrote the foreword to the 'Official Guidebook' of the Romney, Hythe and Dymchurch Railway. In March 2014, he worked on a systematic review of the side effects of statins compared with placebos, published in the European Journal of Preventive Cardiology. Although many newspapers that covered the review said that it found that statins have "virtually no side effects", Goldacre criticized this coverage as inaccurate. For example, he noted that the study relied on data from trial reports, which are likely to be incomplete.
Goldacre contributed to The Atheist's Guide to Christmas (2009), a charity book featuring essays and anecdotes from 42 well-known atheists and apatheists, on the subject of "the power of ideas". He describes himself as an apatheist. He also wrote the foreword to a reissue of Testing Treatments: Better Research for Better Healthcare by Imogen Evans, Hazel Thornton, Iain Chalmers and Paul Glasziou, published by Pinter & Martin in March 2010. He has had several articles published in the British Medical Journal (BMJ) on the MMR vaccine, science journalism, and related topics.
In 2008, Matthias Rath, a vitamin entrepreneur, sued Goldacre and The Guardian over three articles, in which Goldacre criticised Rath's promotion of vitamin pills to AIDS sufferers in South African townships. Rath dropped his action in September 2008 and was ordered to pay initial costs of £220,000 to The Guardian. The paper is seeking full costs of £500,000, and Goldacre has expressed an interest in writing a book about Rath and South Africa, as a chapter on the subject had to be cut from his book while the litigation proceeded. The chapter was reinstated in a later edition of the book, and also published online. Goldacre continues to cite Rath as a proponent of harmful pseudoscience.
Goldacre's first book, Bad Science, was published by Fourth Estate in September 2008. The book contains extended and revised versions of many of his Guardian columns. It was positively reviewed by the British Medical Journal (BMJ) and The Daily Telegraph, and reached the Top 10 bestseller list for Amazon Books. It was nominated for the 2009 Samuel Johnson Prize. In an interview in 2008, Goldacre said that "one of the central themes" of his book [Bad Science] was "that there are no real differences between the $600 billion pharmaceutical industry and the $50 billion food supplement pill industry."
He has been a particularly hardline critic of the nutritionist Gillian McKeith. While investigating McKeith's membership of the American Association of Nutritional Consultants, Goldacre purchased a "certified professional membership" on behalf of his late cat, Henrietta, from the same institution for $60. In February 2007, McKeith agreed to stop using the title "Doctor" in her advertising, following a complaint to the Advertising Standards Authority by a "Bad Science" reader. In an interview with Richard Saunders of the podcast Skeptic Zone, Goldacre said, "Nutritionists are particularly toxic because they are the alternative therapists who, more than any other, misrepresent themselves as being men and women of science."
Goldacre passed the Member of the Royal College of Psychiatrists (MRCPsych) Part II examinations in December 2005 and became a member of the Royal College of Psychiatrists. He was made a research fellow at the Institute of Psychiatry in London in 2008, and a Guardian research fellow at Nuffield College, Oxford, in 2009.
Goldacre is known in particular for his Bad Science column in The Guardian, which he wrote between 2003 and 2011, and is the author of four books: Bad Science (2008), a critique of irrationality and certain forms of alternative medicine; Bad Pharma (2012), an examination of the pharmaceutical industry, its publishing and marketing practices, and its relationship with the medical profession; I Think You'll Find It's a Bit More Complicated Than That, a collection of his journalism; and Statins, about evidence-based medicine. Goldacre frequently delivers free talks about bad science—he describes himself as a "nerd evangelist".
Goldacre was known for his weekly column, "Bad Science", which ran in the Saturday edition of The Guardian from 2003 until November 2011. The column focused on pseudoscience and the misuse of science. Topics discussed included marketing, the media, quackery, problems with the pharmaceutical industry, and its relationship with medical journals.
Goldacre was a visiting researcher in cognitive neuroscience at the University of Milan, working on fMRI brain scans of language and executive function. Following his studies at the Universities of Oxford and Milan, Goldacre studied clinical medicine at UCL Medical School, qualifying as a medical doctor in 2000 with a Bachelor of Medicine, Bachelor of Surgery (MB, BS) degree. He also received a Master of Arts degree in philosophy from King's College London in 1997.
Goldacre was educated at Magdalen College School, Oxford. He studied medicine at Magdalen College, Oxford, where he obtained a first-class Bachelor of Arts honours degree during his preclinical studies in 1995 in Physiological Sciences. He edited the Oxford student magazine, Isis.
Ben Michael Goldacre MBE (born 20 May 1974) is a British physician, academic, and science writer. As of March 2015, he is a senior clinical research fellow at the Centre for Evidence-Based Medicine, part of the University of Oxford's Nuffield Department of Primary Care Health Sciences. He is a founder of the AllTrials campaign and OpenTrials to require open science practices in clinical trials.
Goldacre is the son of Michael Goldacre, a professor of public health at the University of Oxford, and Susan Traynor (stage name Noosha Fox) lead singer of 1970s pop band Fox, both of whom are Australian. He is the nephew of Robyn Williams, a science journalist, and the great-great-grandson of Sir Henry Parkes, politician and journalist who is considered the father of the Australian Federation. He has two children.